Can someone explain why it's taken so long to go from the success CAR-T had with non solid tumors, to getting an immunotherapy that indeed is effective against solid tumors?
>> The FDA indicated that patients and participants in clinical trials receiving CAR T-cell therapy should be monitored life-long for secondary malignancies.
https://www.onclive.com/view/fda-requires-boxed-warning-for-...
Regarding solid tumors, I've only hear about T-cell exhaustion, but CAR-T solid tumor trials are ongoing:
https://med.stanford.edu/cancer/about/news/car-t-solid-tumor...
>> Although CAR T-cells directed toward the HER2-expressing tumors have been extensively studied in clinical trials, safety concerns have emerged following the death of a CRC patient who received 1×1010 third-generation HER2-CAR T-cells.